A very interesting development.
I was chatting to my very old friend, as in the number of years, Richard Maugham yesterday and shortly after the call he sent me an email with a link to a recent item on the BBC News website.
Most of you regulars know that Jeannie was diagnosed with Parkinson’s disease (PD) in December, 2015 and coincidentally at the same time Richard was also diagnosed with PD.
I’m sure there are a few who read this blog that either have PD of know or someone who has it.
Prostate drug may slow Parkinson’s disease
By Michelle Roberts,
Health editor, BBC News online
17th September, 2019
A drug used to treat enlarged prostates may be a powerful medicine against Parkinson’s disease, according to an international team of scientists.
Terazosin helps ease benign prostatic hyperplasia (BPH) by relaxing the muscles of the bladder and prostate.
But researchers believe it has another beneficial action, on brain cells damaged by Parkinson’s.
They say the drug might slow Parkinson’s progression – something that is not possible currently.
They studied thousands of patients with both BPH and Parkinson’s.
Their findings, published in the Journal of Clinical Investigation, suggest the alpha-blocker drug protects brain cells from destruction.
Parkinson’s is a progressive condition affecting the brain, for which there is currently no cure.
Existing Parkinson’s treatments can help with some of the symptoms but can’t slow or reverse the loss of neurons that occurs with the disease.
Terazosin may help by activating an enzyme called PGK1 to prevent this brain cell death, the researchers, from the University of Iowa, in the US and the Beijing Institute for Brain Disorders, China, say.
When they tested the drug in rodents it appeared to slow or stop the loss of nerve cells.
To begin assessing if the drug might have the same effect in people, they searched the medical records of millions of US patients to identify men with BPH and Parkinson’s.
They studied 2,880 Parkinson’s patients taking terazosin or similar drugs that target PGK1 and a comparison group of 15,409 Parkinson’s patients taking a different treatment for BPH that had no action on PGK1.
Patients on the drugs targeting PGK1 appeared to fare better in terms of Parkinson’s disease symptoms and progression, which the researchers say warrants more study in clinical trials, which they plan to begin this year.
Lead researcher Dr Michael Welsh says while it is premature to talk about a cure, the findings have the potential to change the lives of people with Parkinson’s.
“Today, we have zero treatments that change the progressive course of this neurodegenerative disease,” she says.
“That’s a terrible state, because as our population ages Parkinson’s disease is going to become increasingly common.
“So, this is really an exciting area of research.”
Given that terazosin has a proven track record for treating BPH, he says, getting it approved and “repurposed” as a Parkinson’s drug should be achievable if the clinical trials go well.
The trials, which will take a few years, will compare the drug with a placebo to make sure it is safe and effective in Parkinson’s.
Co-researcher Dr Nandakumar Narayanan, who treats patients with Parkinson’s disease said: “We need these randomised controlled trials to prove that these drugs really are disease modifying.
“If they are, that would be a great thing.”
Prof David Dexter from Parkinson’s UK said: “These exciting results show that terazosin may have hidden potential for slowing the progression of Parkinson’s, something that is desperately needed to help people live well for longer.
“While it is early days, both animal models and studies looking at people who already take the drug show promising signs that need to be investigated further.”
I have now written to the Journal of Clinical Investigation, (JCI).
Interestingly, if one goes to the website of the JCI then one reads the following on the ‘About’ page:
The Journal of Clinical Investigation is a premier venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.
The JCI was founded in 1924 and is published by the ASCI, a nonprofit honor organization of physician-scientists incorporated in 1908. See the JCI’s Wikipedia entry for detailed information.
- Impact Factor: 12.282 (2018). The JCI is one of the top journals in the “Medicine, Research & Experimental” category.
- Broad readership and scope. The JCI reaches readers across a wide range of medical disciplines and sectors. The journal publishes basic and phase I/II clinical research submissions in all biomedical specialties, including Autoimmunity, Gastroenterology, Immunology, Metabolism, Nephrology, Neuroscience, Oncology, Pulmonology, Vascular Biology, and many others.
- Open access. All research is available to the public for free. The JCI deposits published research articles in PubMed Central, which satisfies the NIH Public Access Policy and other similar funding agency requirements.
It’s a small step forward!